215 related articles for article (PubMed ID: 17121451)
1. What is the best approach to reducing birth defects associated with isotretinoin?
Abroms L; Maibach E; Lyon-Daniel K; Feldman SR
PLoS Med; 2006 Nov; 3(11):e483. PubMed ID: 17121451
[TBL] [Abstract][Full Text] [Related]
2. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
3. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
4. Continued occurrence of Accutane-exposed pregnancies.
Honein MA; Paulozzi LJ; Erickson JD
Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
[TBL] [Abstract][Full Text] [Related]
5. [Pregnancy after isotretinoin use].
Manders KC; de Vries LC; Roumen FJ
Ned Tijdschr Geneeskd; 2013; 157(41):A6567. PubMed ID: 24103139
[TBL] [Abstract][Full Text] [Related]
6. Compliance with pregnancy prevention measures during isotretinoin therapy.
Collins MK; Moreau JF; Opel D; Swan J; Prevost N; Hastings M; Bimla Schwarz E; Korb Ferris L
J Am Acad Dermatol; 2014 Jan; 70(1):55-9. PubMed ID: 24157382
[TBL] [Abstract][Full Text] [Related]
7. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
[TBL] [Abstract][Full Text] [Related]
8. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
9. Accutane-exposed pregnancies--California, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jan; 49(2):28-31. PubMed ID: 10680601
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
11. Isotretinoin revisited.
Shalita AR; Armstrong RB; Leyden JJ; Pochi PE; Strauss JS
Cutis; 1988 Dec; 42(6A):1-19. PubMed ID: 2974796
[TBL] [Abstract][Full Text] [Related]
12. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study.
Cheetham TC; Wagner RA; Chiu G; Day JM; Yoshinaga MA; Wong L
J Am Acad Dermatol; 2006 Sep; 55(3):442-8. PubMed ID: 16908350
[TBL] [Abstract][Full Text] [Related]
13. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
Brinker A; Kornegay C; Nourjah P
Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
[TBL] [Abstract][Full Text] [Related]
14. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
15. Accutane risk management program strengthened.
FDA Consum; 2002; 36(1):8. PubMed ID: 11881607
[No Abstract] [Full Text] [Related]
16. A pox on your practice. iPLEDGE program scars dermatologists.
Ortolon K
Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
[No Abstract] [Full Text] [Related]
17. iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system.
Schonfeld TL; Amoura NJ; Kratochvil CJ
J Law Med Ethics; 2009; 37(1):104-17. PubMed ID: 19245607
[TBL] [Abstract][Full Text] [Related]
18. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.
BĂ©rard A; Azoulay L; Koren G; Blais L; Perreault S; Oraichi D
Br J Clin Pharmacol; 2007 Feb; 63(2):196-205. PubMed ID: 17214828
[TBL] [Abstract][Full Text] [Related]
19. Possible long-term teratogenic effect of isotretinoin in pregnancy.
Malvasi A; Tinelli A; Buia A; De Luca GF
Eur Rev Med Pharmacol Sci; 2009; 13(5):393-6. PubMed ID: 19961047
[TBL] [Abstract][Full Text] [Related]
20. Women's experiences with isotretinoin risk reduction counseling.
Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]